Home / Health / Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial
Next-Gen Diabetes Drug CagriSema Beats Wegovy in Key Trial
2 Feb
Summary
- CagriSema achieved greater weight loss than Wegovy in a type 2 diabetes trial.
- The new drug also demonstrated superior reduction in blood sugar levels.
- CagriSema combines active ingredients from two different mimic hormones.
In a significant development for type 2 diabetes treatment, Novo Nordisk's next-generation drug, CagriSema, has demonstrated superior efficacy over its current blockbuster, Wegovy. A late-stage trial revealed that CagriSema, administered in a high-dose weekly injection, facilitated approximately 14.2% body weight loss in participants over 68 weeks, surpassing Wegovy's 10.2% reduction.
This experimental therapy combines cagrilintide and semaglutide, mimicking pancreatic and gut hormones, respectively. Beyond weight management, CagriSema also proved more effective in controlling blood sugar. Participants receiving CagriSema saw a 1.91 percentage point drop in HbA1c levels, compared to a 1.76 percentage point decrease with semaglutide alone. The trial involved 2,728 individuals with type 2 diabetes already on standard treatments.
